Hillgene Reached a Strategic Cooperation with T-Maximum in Accelerating the innovation and Breakthrough of Universal Cells

Recently, Jiangsu Puxin Biopharmaceutical Co., Ltd. (hereinafter referred to as "Puxin Biopharmaceutical") and Maoxing Biopharmaceutical Technology Co., Ltd. (hereinafter referred to as "Maoxing Biopharmaceutical") held a strategic cooperation signing ceremony. Based on the good test and analysis data of the commissioned project in the early stage, the two parties will officially carry out in-depth cooperation on the commissioned development and production project of universal cell drugs. Puxin will undertake pharmaceutical development and promote IND filing in China and the United States.

Dr. Shang Xiaoyun, CEO of Maoxing Bio, said: "The strategic cooperation between Maoxing Bio and Spectrum Bio will have a positive impact on the development of both companies and the development of new cell drugs. Maoxing Bio has always adhered to the differentiated development path driven by innovation, exploring the treatment of solid tumors with a universal cell technology platform, and has applied for a number of innovative patents internationally. The preliminary proof-of-concept clinical studies have also achieved encouraging results. We hope that through this strategic cooperation, we can give full play to our respective advantages and promote Chinese innovation to the international stage at the fastest speed. This cooperation with Spectrum Bio will accelerate the clinical research and listing process of the pipeline, promote the dual filing in China and the United States, and is of milestone significance."

Spectrum Bio has a professional CQDMO (Contract Development, Manufacturing and Quality Control) technical service platform and rich project experience. This strategic cooperation will make full use of the respective advantages of both parties, deepen cooperation and promote the potential of universal CAR-T, and hope to bring more effective new immunotherapy options to patients in the future.

About Maoxing Bio

Maoxing Bio is a clinical-stage cell therapy development company co-founded by well-known experts in the fields of immunotherapy, gene editing, and biopharmaceuticals and senior operation and management personnel of biological companies, and is committed to the development of new immune cell therapy technologies. The company's core technology platform, gene-edited allogeneic immune cell therapy, adopts the 3.0 version of the program with completely independent intellectual property rights to achieve allogeneic universal CAR-T treatment, solve the risk of graft-versus-host disease and rejection of allogeneic immune cells, and the obtained allogeneic CAR-T cells can be maintained in the patient's body for a long time, thereby exerting ideal therapeutic effects, which is at the international leading level. The company was selected for the 2018 Suzhou "Gusu Innovation and Entrepreneurship Leading Talent Program" and the 2019 Suzhou Industrial Park Entrepreneurship Leading Talent Program, and won awards in multiple national entrepreneurship competitions. Maoxing Bio's core technology has published a series of papers in top journals such as Nature, Nature Biotechnology, Nature Methods, and Cell, and applied for more than 30 international PCT and national invention patents. The company is currently focusing on intracranial tumors, and the first product pipeline for recurrent gliomas has achieved breakthrough efficacy and controllable safety verification in preliminary clinical studies. The company plans to promote at least one product to market in the next five years and promote multiple products to enter the clinical phase II research stage.

About Spectrum Bio

Headquartered in Wuzhong District, Suzhou City, on the shore of the beautiful Taihu Lake, Spectrum Bio has Suzhou headquarters (10,000 square meters of GMP plant and R&D center), Shenzhen and Shanghai bases, initially forming a nationwide production base network layout; the North Carolina base in the United States is also under construction, and the global layout is being carried out simultaneously. It has built a nucleic acid platform dedicated to cell drugs, a suspended serum-free virus production platform, a fully enclosed cell process development platform and a quality control and testing technology platform, creating a highway for cell drugs from discovery to product delivery. The platform has supported multiple partners to successfully incubate a number of CAR-T, TCR-T, stem cell and other drugs. Spectrum Bio is committed to allowing more projects to reach the next milestone earlier and faster, bringing more cell drugs to the market, benefiting more patients, and allowing cell drugs to write a new chapter in life.